June 24 - Cassidy challenges RFK, Amgen disappoints Wall Street and another FDA exit

New Amgen obesity drug data disappoint Wall Street; Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug; Top drug official at FDA reportedly set to exit next month; Compass’ big psychedelic study doesn’t impress investors

View online | Signup

Daily Dive

June 24, 2025 | Today’s news and insights for biopharma leaders

BROUGHT TO YOU BY — McKesson Compile

Discover where NPs and PAs specialize in oncology

Go beyond the limits of taxonomy codes. New data spotlights the NPs and PAs treating cancer patients in leading U.S. health systems. Download for free.

Cassidy challenges RFK Jr. with call for delay to CDC vaccine meeting

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from medical groups and Democratic lawmakers.

New Amgen obesity drug data disappoint Wall Street

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss effects that weren’t as strong as previously reported.

Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung cancer, a crowded indication with uncertain sales potential.

Unlock the benefits of direct-to-patient clinical supply

Catalent FlexDirect® allows clinical supplies to be delivered directly to patients’ homes, minimizing or removing the need for clinical site visits.
Discover more about DTP.

Top drug official at FDA reportedly set to exit next month

Jacqueline Corrigan-Curay, who serves as acting head of the powerful CDER office, will leave after nearly a decade at the agency.

Compass’ big psychedelic study doesn’t impress investors

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s version of psilocybin could be as a depression treatment.

Building a Patient-Focused Brand in a Competitive Market

In today’s competitive pharmaceutical market, creative omnichannel campaigns help brands stand out amid complex regulations. Discover how to innovate strategies to drive growth in this playbook.

Download Now

From Our Library

Playbook